1-5 of 5
Esther C.W. Breij
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy

Jantine E. Bakema, Marijke Stigter-van Walsum, Jeffrey R. Harris, Sonja H. Ganzevles, Anantharaman Muthuswamy, Mischa Houtkamp, Theo S. Plantinga, Elisabeth Bloemena, Ruud H. Brakenhoff, Esther C.W. Breij, Rieneke van de Ven
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (2): 187–198.
https://doi.org/10.1158/1535-7163.MCT-23-0298
Published: 01 February 2024
View articletitled, An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy
Open the PDF for An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract IA004: Preclinical development of DuoBody®-CD3xB7H4, a novel CD3 bispecific antibody for the treatment of solid cancers

Louise A Koopman, Farshid Alemdehy, Madelon Paauwe, Laura Smits-de Vries, Frosso Karaiskaki, Marcel Brandhorst, Patrick Franken, Theo S Plantinga, Mischa A Houtkamp, Stefanie A.H. de Poot, Esther C.W. Breij
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): IA004.
https://doi.org/10.1158/1535-7163.TARG-23-IA004
Published: 01 December 2023
View articletitled, Abstract IA004: Preclinical development of DuoBody®-CD3xB7H4, a novel CD3 bispecific antibody for the treatment of solid cancers
Journal Articles

Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism

Marije B. Overdijk, Kristin Strumane, Frank J. Beurskens, Antonio Ortiz Buijsse, Claudine Vermot-Desroches, Boris S. Vuillermoz, Thessa Kroes, Bart de Jong, Naomi Hoevenaars, Richard G. Hibbert, Andreas Lingnau, Ulf Forssmann, Janine Schuurman, Paul W.H.I. Parren, Rob N. de Jong, Esther C.W. Breij
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (10): 2126–2138.
https://doi.org/10.1158/1535-7163.MCT-20-0044
Published: 02 October 2020
View articletitled, Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
Open the PDF for Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism in another window
Includes: Supplementary data
Journal Articles

Abstract C025: HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor models

Marije B Overdijk, Michael Cecchini, Kristin Strumane, Marcel Brandhorst, Andreas Lingnau, Paul W.H.I. Parren, Merete Ellekilde-Pedersen, Ulf Forssmann, Tahamtan Ahmadi, A. Kate Sasser, Janine Schuurman, Esther C.W. Breij, Patricia LoRusso
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C025.
https://doi.org/10.1158/1535-7163.TARG-19-C025
Published: 01 December 2019
View articletitled, Abstract C025: HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor models
Journal Articles

Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63

Bart E.C.G. de Goeij, Tom Vink, Hendrik ten Napel, Esther C.W. Breij, David Satijn, Richard Wubbolts, David Miao, Paul W.H.I. Parren
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2688–2697.
https://doi.org/10.1158/1535-7163.MCT-16-0364
Published: 01 November 2016
View articletitled, Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
Open the PDF for Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63 in another window
Includes: Supplementary data